SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit

14 May 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development

10 May 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

06 May 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio

06 May 2021 05:04:47 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

01 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer

22 Mar 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

25 Feb 2021 05:45:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

25 Feb 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

22 Feb 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day

04 Feb 2021 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 05:30:00 By Nasdaq GlobeNewswire